Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2010-04-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including cash flows related to operating, investing, and financing activities for the quarter ended 31 March 2010. It includes actual financial statements and reconciliations, director payments, and compliance statements. The document is approximately 6960 characters long, which is sufficient to contain substantive financial data. The content aligns with a quarterly financial report rather than a brief announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2010
2010-04-29 English
Mr Nick Woolf Appointed Non Executive Director 2 pages ?Kb
Board/Management Information Classification · 100% confidence The document is an announcement dated 22 April 2010 about the appointment of Mr Nick Woolf as a Non Executive Director of Phylogica Limited. It contains biographical details and statements from the Chairman but does not include any financial data, report content, or regulatory filings. The primary focus is on a change in the company's board of directors. The document length is 3193 characters, which is relatively short and consistent with a management or board change announcement rather than a full report or detailed filing. Therefore, the appropriate classification is Board/Management Information (MANG).
2010-04-21 English
Initial Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, specifically noting 'Nil' holdings. This matches the description of a Director's Dealing report, which involves reporting personal share transactions or interests by company directors. The document length is short and focused solely on director interests, with no financial statements or other report content. Therefore, it fits the Director's Dealing (DIRS) category.
2010-04-21 English
Finance News Network Interview with CEO and Chairman 4 pages ?Kb
Call Transcript Classification · 95% confidence The document is a transcript of an interview with the CEO and Executive Chairman of Phylogica Limited, discussing the company's business model, drug discovery focus, recent deals, financial burn rate, and market capitalization. It is a full text transcript of a company communication, not a financial report, regulatory filing, or announcement. The content matches the characteristics of a Call Transcript (CT) as it is a detailed Q&A style interview providing insights into company operations and strategy.
2010-04-07 English
Road Show Investor Presentation 36 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Phylogica Ltd dated 21 March 2010, discussing drug development, biotech models, biologics, peptides, and the company's proprietary technology and market positioning. It contains extensive explanatory text, charts, and strategic information about the company's technology and market trends. There is no indication that this is a formal financial report like an Annual Report (10-K) or Interim Report (IR), nor is it an earnings release or regulatory filing. The content is educational and promotional, focusing on company strategy, technology, and market opportunity, which aligns with an Investor Presentation (IP). The length (15,000 characters) and detailed content support this classification rather than a brief announcement or report publication notice.
2010-03-21 English
Change of Director`s Interest Notice 2 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y' and is a 'Change of Director’s Interest Notice' for PHYLOGICA LIMITED. It details the change in securities held by a director, including the number of shares before and after the change, the nature of the change (on-market purchase), and references to ASX listing rules and the Corporations Act. This type of document is a report of personal share transactions by company directors and executives, which matches the definition of 'Director's Dealing' filings. The document length is under 5,000 characters and contains detailed transaction data, confirming it is not merely an announcement but the actual report of the transaction.
2010-03-16 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.